NCT07518173 2026-04-08A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerSichuan Baili Pharmaceutical Co., Ltd.Phase 3 Not yet recruiting596 enrolled
NCT03975647 2026-03-30A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeagen Inc.Phase 3 Active not recruiting466 enrolled 17 charts
NCT07043725 2026-03-27A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerChia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3 Recruiting544 enrolled